Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New pill could help women regrow hair – but It's not a cure

NCT ID NCT07146022

Disease control Sponsor: Veradermics, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 18, 2026 · Updated 2 times

Summary

This study tests an oral drug called VDPHL01 in 552 women aged 18–65 with mild to moderate hereditary hair loss. Participants take a pill once or twice daily for about 13 months. The goal is to see if it increases hair count and if women feel their hair looks better. It's a placebo-controlled, double-blind trial, meaning neither participants nor doctors know who gets the real drug.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
VDPHL01 (an oral tablet)
What this could lead to
If it works, this could provide a new daily pill to help women with hereditary hair loss regrow hair and feel better about their appearance.
What could go wrong
This is a Phase 3 trial, but it's still experimental. The drug may not work better than placebo, and side effects are possible. Results are based on hair counts and self-assessment, not a cure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 552 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2025

Expected to finish

Jan 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Subject is a female aged 18-65 years old; * Subject has a clinical diagnosis of mild to moderate AGA; * Subject is in good general health and has adequate renal and hepatic function; * Subject is willing to maintain at least 1/4 inch length hair during the study with the same hairstyle, hair length, and hair color throughout the study; maintain consistent use of general hair care products and regimen through the entire study; * Subject is willing and able to administer the test article as directed and can read, understand, and complete the required questionnaires in English; * Subject is willing and able to swallow study drug whole; * Subject agrees to have a micro dot tattoo placed on their scalp; * Subject agrees to have this area photographed at study visits as indicated in the protocol. Exclusion Criteria: * Subject has uncontrolled blood pressure or orthostatic hypotension; * Subject has symptoms or history of certain heart or thyroid conditions; * Subject has a history of or active hair loss due to conditions/diseases other than AGA; * Subject has a current or recent history of dietary or weight changes, including use of GLP-1 agonists; * Subject has been diagnosed with COVID-19 within 16 weeks of baseline; * Subject has had previous radiation of the scalp; * Use of any of the following treatments within the indicated washout period before screening: * Subject has used hormone replacement therapy or hormonal modulators within 6 months prior to screening * Subject has used oral treatments for hair growth or that can affect hair growth, including systemic retinoids, within 6 months of screening * Subject has used systemic calcium channel blockers or beta blockers within 12 weeks prior to screening * Subject has used systemic cimetidine, ketoconazole, diazoxide, or corticosteroids (including intramuscular, intraarticular, and intralesional injections) within 12 weeks prior to screening * Subject has had any scalp procedures, including surgical, laser, light or energy treatments, micro-needling, injections, platelet rich plasma within 6 months prior to screening * Subject has used any topical scalp treatments for hair growth within 12 weeks prior to screening * Subject has used any other therapy with any medication either topical or oral that might, in the investigator's opinion, interfere with the study; * Subject has any other condition that, in the investigator's opinion, interfere with the study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AGA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

alopecia androgenetic alopecia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AGA Androgenetic alopecia Androgenetic alopecia (AGA) Female androgenetic alopecia Hair loss

Contacts and locations

Locations

  • Site 11

    Columbus, Ohio, 43215, United States

  • Site 12

    Metairie, Louisiana, 70006, United States

  • Site 13

    Covington, Louisiana, 70433, United States

  • Site 14

    Houston, Texas, 77056, United States

  • Site 15

    Indianapolis, Indiana, 46250, United States

  • Site 17

    Aventura, Florida, 33180, United States

  • Site 18

    Hackensack, New Jersey, 07601, United States

  • Site 19

    South Jordan, Utah, 84095, United States

  • Site 2

    Fremont, California, 94538, United States

  • Site 21

    Vista, California, 92083, United States

  • Site 22

    Brighton, Massachusetts, 02135, United States

  • Site 24

    Greenwood Village, Colorado, 80111, United States

  • Site 26

    Clarkston, Michigan, 48346, United States

  • Site 27

    West Lafayette, Indiana, 47906, United States

  • Site 29

    Forest, Virginia, 24551, United States

  • Site 30

    Fort Smith, Arkansas, 72916, United States

  • Site 31

    Boise, Idaho, 83704, United States

  • Site 32

    New Albany, Indiana, 47150, United States

  • Site 33

    Burien, Washington, 98168, United States

  • Site 34

    Sherman Oaks, California, 91403, United States

  • Site 37

    Kew Gardens, New York, 11415, United States

  • Site 39

    Boardman, Ohio, 44512, United States

  • Site 4

    Nashville, Tennessee, 37215, United States

  • Site 41

    Baton Rouge, Louisiana, 70809, United States

  • Site 43

    Atlanta, Georgia, 30329, United States

  • Site 5

    Castle Rock, Colorado, 80109, United States

  • Site 52

    Louisville, Kentucky, 40241, United States

  • Site 53

    Clarksville, Indiana, 47129, United States

  • Site 54

    Ocala, Florida, 34470, United States

  • Site 55

    Plainfield, Indiana, 46168, United States

  • Site 56

    Minneapolis, Minnesota, 55455, United States

  • Site 57

    Portland, Oregon, 97210, United States

  • Site 59

    Quincy, Massachusetts, 02169, United States

  • Site 6

    New Brighton, Minnesota, 55112, United States

  • Site 60

    Anderson, South Carolina, 29621, United States

  • Site 61

    Chicago, Illinois, 60610, United States

  • Site 62

    Coral Gables, Florida, 33146, United States

  • Site 63

    Norfolk, Virginia, 23502, United States

  • Site 64

    Manhattan Beach, California, 90266, United States

  • Site 66

    Santa Monica, California, 90404, United States

  • Site 67

    Dallas, Texas, 75230, United States

  • Site 68

    Clinton Township, Michigan, 48038, United States

  • Site 69

    Encino, California, 91436, United States

  • Site 70

    Mill Creek, Washington, 98012, United States

  • Site 71

    Boca Raton, Florida, 33486, United States

  • Site 72

    Cincinnati, Ohio, 45236, United States

  • Site 73

    Birmingham, Alabama, 35209, United States

  • Site 74

    College Station, Texas, 77845, United States

  • Site 75

    New Orleans, Louisiana, 70124, United States

  • Site 76

    Austin, Texas, 78746, United States

  • Site 77

    Phoenix, Arizona, 85006, United States

  • Site 79

    Leawood, Kansas, 66211, United States

  • Site 80

    Chestnut Hill, Massachusetts, 02467, United States

  • Site 82

    Hickory, North Carolina, 28602, United States

  • Site 83

    Southfield, Michigan, 48034, United States

  • Site 84

    Glenn Dale, Maryland, 20769, United States

  • Site 85

    Norfolk, Virginia, 23502, United States

  • Site 86

    Coral Gables, Florida, 33134, United States

  • Site 87

    Rockville, Maryland, 20850, United States

  • Site 88

    San Antonio, Texas, 78218, United States

  • Site 89

    Birmingham, Alabama, 35244, United States

  • Site 9

    Knoxville, Tennessee, 37909, United States

  • Site 90

    Sandy Springs, Georgia, 30328, United States

  • Site 91

    Sugar Land, Texas, 77479, United States

  • Site 92

    Huntersville, North Carolina, 28078, United States

  • Site 93

    Northridge, California, 91324, United States

  • Site 94

    Thousand Oaks, California, 91320, United States

  • Site 95

    Hermitage, Tennessee, 37076, United States

  • Site 97

    New York, New York, 10003, United States

  • Site 98

    Medina, Minnesota, 55340, United States

  • Site 99

    Miami, Florida, 33173, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.